Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease

Current Alzheimer Research

Volumn 4, Issue 2, 2007, Pages 191-197

  Deane, Rashid ^a   Zlokovic, Berislav V ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

AD; Aging; Amyloid ; BBB; Cerebrovascular; LRP1; RAGE; sLRP

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID PROTEIN ANTIBODY; GANGLIOSIDE GM1; GELSOLIN; GLYCOPROTEIN P; HOMEODOMAIN PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MYOCARDIN; PROTEIN ANTIBODY; PROTEIN GROWTH ARREST SPECIFIC HOMEOBOX; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID NEUROPATHY; ANGIOGENESIS; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; CLINICAL FEATURE; DRUG MECHANISM; ENCEPHALITIS; HOMEOSTASIS; HUMAN; NERVE CELL INHIBITION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVIEW; VASCULAR AMYLOIDOSIS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIGENS, NEOPLASM; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; HUMANS; LDL-RECEPTOR RELATED PROTEIN 1; MITOGEN-ACTIVATED PROTEIN KINASES; P-GLYCOPROTEIN;

EID: 34147183707     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720507780362245     Document Type: Review

References (95)

1. Begley DJ, Brightman M. Structural and functional aspects of the blood-brain barrier: Progress in Drug Research (Ed: L. Prokai and K. Prokai-Tatrai) Birkhause Velag, Basel 61:40-78 (2003).
2. Zlokovic BV and Frangione B. Transport-clearance hypothesis for Alzheimer's disease and potential therapeutic implications. Aβ Metabolism in Alzheimer's Disease. (Ed. T. Saido). Landes Bioscience. 114-122 (2003).
3. Zlokovic BV. Clearing amyloid through the blood-brain barrier. J Neurochem 89: 807-811 (2004).
4. Tanzi RE, Moir RD and Wagner SL. Clearing of Alzheimer's Aβ peptide; the many roads to perdiction. Neuron 43: 605-608 (2004).
5. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 28: 202-208 (2005).
6. Ghiso J and Frangione B. Amyloidosis in Alzheimer's Disease. Adv Drug Del Rev 54:1539-1553 (2002).
7. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nature Med 9(7):907-913 (2003).
8. 1- 40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106:1489-1499 (2000).
9. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295:2264-2267 (2002).
10. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, et al. LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron 43: 333-344 (2004).
11. Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron 32:177-180 (2001).
12. Iwata N, Higuchi M, Saido TC. Metabolism of amyloid-β peptide and Alzheimer's disease. Pharmacol Therap108:129-148 (2005).
13. Iwata N, Tsubuki S, Takaki Y, et al. Metabolic regulation of brain Aβ by neprilysin. Science 292:1550-1552 (2001).
14. Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sui X, Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40: 1087-1093 (2003).
15. Silverberg GD, Mayo M, Saul T, Rubenstein E and McGuire D. Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol 2:506-511 (2003).
16. Hardy J and Selkoe DJ. The amyloid hypothesis of Alzheimer's disease progress and problems on the road to therapeutics. Science 297: 353-356 (2002).
17. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-489 (2003).
18. Martel CL, Mackic JB, Matsubara E, Governale S, Miguel C, Miao W, et al. Isoform-specific effects of apolipoproteins E2, E3, E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid β. J Neurochem 69:1995-2004 (1997).
19. Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, et al. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer's disease amyloid-β at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci USA 93:4229-4234 (1996).
20. Zlokovic BV, Frangione B and Ghiso J. In: Blood-brain barrier transport of Alzheimer's amyloid-β. Cerebral Amyloid Angiopathy and Alzheimer's Disease. (Ed. Verebek M.). 325-347 (2000).
21. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, et al. APP locus duplication causes autosomal dominant earlyonset Alzheimer's disease with cerebral amyloid angiopathy. Nat Genet 38: 24-26 (2006).
22. Hardy J. Amyloid double trouble. Nat Med 38:11-12 (2006).
23. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 275:630-631 (1997).
24. Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenlin in Alzheimer's disease. Trends Cell Biol 8:447-453 (1998).
25. Hardy J, Duff K, Hardy KG, Perez-Tur J, Hutton M. Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nature Neurosci 1:355-358 (1998).
26. Roses AD. Alzheimer diseases: a model of gene mutations and susceptibility polymorphisms for complex psychiatric diseases. Am J Med Genet 81:49-57 (1998).
27. Younkin SG. The role of Aβ42 in Alzheimer's disease. J Physiol 92:289-292 (1998).
28. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399:23-31 (1999).
29. DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, et al. ApoE and clusterin cooperatively suppress Aβ levels and deposition: evidence that apoE regulates extracellular Aβ metabolism in vivo. Neuron 41:193-202 (2004).
30. Fryer JD, Demattos RB, McCormick LM, O'Dell MA, Spinner ML, Bales KR, et al. The low density lipoprotein receptor regulates the level of central nervous system human and murine apoliprotein E but does not modify amyloid plaque pathology in PDAPPmice. J Biol Chem 280: 25754-25759 (2005).
31. Zlokovic BV, Yamada S, Holtzman D, Ghiso J and Frangione B. Clearance of amyloid-β peptide from brain: transport or metabolism? Nature Med 6:718-719 (2000).
32. Deane R, Wu Z, and Zlokovic BV. RAGE (YIN) versus LRP (YANG) balance regulates Alzheimer amyloid β-peptide clearance through transport across the blood-brain barrier. Stroke 35: 2628-2631 (2004).
33. Holtzman DM and Zlokovic BV. In: Alzheimer's disease: Advances in genetics, molecules and cellular biology. (Eds. S. Sisodia, R. Tanzi.) Springer (2006) Chapter 11.
34. Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, et al. Role of MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer's disease. Nat Med 11: 959-965 (2005).
35. Ray WJ, Yao M, Mumm J, Schroeter EH, Saftig P, Wolfe M, et al. Cell surface presenilin-1 participates in the gamma-secretase-like proteolysis of Notch. J Biol Chem 274:36801-36807 (1999).
36. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735-741 (1999).
37. Roberts SB. γ-Secretase inhibitors and Alzheimer's disease. Adv Drug Del Rev 54:1579-1588 (2002).
38. Vassar R. β-Secretase (BACE) as a drug target for Alzheimer's disease. Adv Drug Del Rev 54:1589-1602 (2002).
39. Zlokovic BV, Ghiso J, Mackic JB, McComb JG, Weiss MH, Frangione B. Blood-brain barrier transport of circulating Alzheimer's amyloid-β. Biochem Biophys Res Comm 197:1034-1040 (1993).
40. Zlokovic BV, Martel CL, Mackic JB, Matsubara E, Wisniewski T, McComb JG, et al. Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid-β. Biochem Biophys Res Comm 205:1431-1437 (1994).
41. Maness LM, Banks WA, Podlisny MB, Selkoe DJ, Kastin AJ. Passage of human amyloid-β protein 1-40 across the murine blood-brain barrier. Life Sci 55:1643-1650 (1994).
42. Martel CL, Mackic JB, McComb JG, Ghiso J, Zlokovic BV. Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid-β in guinea pigs. Neurosci Lett 206:157-160 (1996).
43. Ghilardi JR, Catton M, Stimson ER, Rogers S, Walker LC, Maggio JE, et al. Intra-arterial infusion of 125I Aβ1-40 labels deposits in the aged primate brain in vivo. Neuroreport 7: 2607-2611 (1996).
44. Ghersi-Egea JF, Gorevic PD, Ghiso J, Frangione B, Patlak CS, Fenstermacher JD. Fate of cerebrospinal fluid-borne amyloid β-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J Neurochem 67:880-883 (1996).
45. Zlokovic BV. Can blood-brain barrier play a role in the development of cerebral amyloidosis and Alzheimer's disease pathology. Neurobiol Dis 4:23-26 (1997).
46. Shayo M, McLay RN, Kastin AJ, Banks WA. The putative bloodbrain-barrier transporter for the β-amyloid binding protein apolipoprotein J is saturated at physiological concentrations. Life Sci 60:L115-L118 (1997).
47. Poduslo JF, Curran GL, Haggard JJ, Biere AL, Selkoe DJ. Permeability and residual plasma volume of human, Dutch variant, and rat amyloid β-protein 1-40 at the blood-brain barrier. Neurobiol Dis 4:27-34 (1997).
48. Mackic JB, Stins M, McComb JG, Calero M, Ghiso J, Kim KS, et al. Human blood-brain barrier receptors for Alzheimer's amyloid-β. J Clin Invest 102:734-743 (1998).
49. Mackic JB, Weiss MH, Miao W, Kirkman E, Ghiso J, Calero M, et al. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid β-peptide in aged squirrel monkey with cerebral amyloid angiopathy. J. Neurochem 70:210-215 (1998).
50. Poduslo JF and Curran GL. Amyloid-β peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier. Neuroreport 12:3197-3200 (2001).
51. Lam FC, Liu R, Lu P, Shapiro AB, Renoir JM, Sharom FJ, et al. β-Amyloid efflux mediated by p-glycoprotein. J Neurochem 76:1121-1128 (2001).
52. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98:8850-8855 (2001).
53. Monro OR, Mackic JB, Yamada S, Segal MB, Ghiso J, Maurer C, et al. Substitution at codon 22 reduces clearance of Alzheimer's amyloid-β peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. Neurobiol Aging 23:405-412 (2002).
54. Mackic JB, Ghiso J, Frangione B, Kirkman L, Bading J, Zlokovic BV. Differential cerebrovascular sequestration and enhanced blood-brain barrier permeability to circulating Alzheimer's amyloid-β peptide in aged Rhesus vs. aged Squirrel monkey. Gen Pharmacology Vasc Biol 18:303-313 (2002).
55. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model. J Clin Invest 115: 3285-3290 (2005).
56. Deane R, Sagare A, Hamm K, Parisi M, LaRue B, Guo H, et al. IgG-assisted age-dependent clearance of Alzheimer's amyloid β peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 25:11495-11503 (2005).
57. Herz J. The LDL receptor gene family: (un)expected signal transducers in the brain. Neuron 29:571-581 (2001).
58. Herz J and Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 108:779-784 (2001).
59. Van der Geer P. Phosphorylation of LRP1: regulation of transport and signal transduction. Trends in Cardiovasc Med 12:160-165 (2002).
60. Bu G, Sun Y, Schwartz AL, Holtzman DM. Nerve growth factor induces rapid increases in functional cell surface low density lipoprotein receptor-related protein. J Biol Chem 273:13359-13365 (1998).
61. Green PS and Bu G. Genetics and molecular biology: phosphorylation of low density lipoprotein receptor-related protein by plateletderived growth factor. Curr Opinion Lipidology 13:569-572 (2002).
62. Hendriks L, van Duijn CM, Cras P, Cruts M, Van Hul W, van Harskamp F, et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nature Genet 1:218-221 (1992).
63. Kang DE, Saitoh T, Chen X, Xia Y, Masliah E, Hansen LA, et al. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology 49:56-61 (1997).
64. Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, et al. Modulation of amyloid β-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 106:1159-1166 (2000).
65. Moir RD and Tanzi RE. LRP-mediated clearance of Abeta is inhibited by KPI-containing isoform of APP. Curr Alzheimer Res 2: 269-273 (2005).
66. 40 in the squirrel monkey: a SPECT study in a primate model of cerebral amyloid angiopathy. J Drug Targeting 10(4): 359-368 (2002).
67. Donahue JE, Flaherty SL, Johanson CE, Duncan JA 3rd, Silverberg GD, Miller MC, et al. RAGE, LRP1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol (Berl) in press (2006).
68. Zerbinatti CV and Bu G. LRP and Alzheimer's disease. Rev Neurosci 6: 123-135 (2005).
69. Davis J, Xu F, Deane R, Romanov G, Previti ML, Zeigler K, et al. Early-onset and robust cerebral microvascular accumulation of amyloid β-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid β-protein precursor. J Biol Chem 279:20296-20306 (2004).
70. Davis J, Xu F, Miao J, Previti ML, Romanov G, Ziegler K, et al. Deficient cerebral clearance of vasculotropic mutant Dutch/Iowa double Aβ in human AβPP transgenic mice. Neurobiol Aging 27: 946-954 (2006).
71. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270:25752-25761 (1995).
72. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel proinflammatory axis: the cell surface receptor for S100/clagranulin polypetides. Cell 97:889-901 (1999).
73. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, et al. Nε-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740-31749 (1999).
74. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382:685-691 (1996).
75. Stern D, Yan SD, Yan SF and Schmidt AM. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Del Rev 54:1615-1625 (2002).
76. Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to β-amyloid. J. Neurosci 23:29-33 (2003).
77. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann Neurol 59: 512-519 (2006).
78. Begley DJ. ABC transporters and the blood-brain barrier. Current Pharmaceutical design 10: 1295-1312 (2004).
79. Vogelgesang S, Cascorbi I, Schroeder E, Pahnke J, Kroemer HK, Siegmund W, et al. Deposittion of Alzheimer's β-amyloid is inversely correlated with P-glycoprotein expression in the brain of elderly non-dementia humans. Pharmacogenetics 12: 535-541 (2002).
80. Vogelgesang S, Warzok RW, Cascorbi I, Kunert-Keil C, Schroeder E, Kroemer HK, et al. The role of P-glycoprotein in cerebral amyloid angiopathy; implications for early pathogenesis of Alzheimer's disease. Curr Alzheimer Res 1: 121-125 (2004).
81. Fernandez C, Buyse M, German-Fattal M, and Gimenez F. Influence of the pro-inflammatory cytokins on P-glycoprotein expression and functionality. J Pharma Sci 7: 359-371 (2004).
82. Bauer B, Hartz AM, Fricker G, Miller DS. Pregnane X receptor upregulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol 66: 413-419 (2004).
83. 11C-verapamil and positron emission tomography. Clin Pharmacol Ther 79: 540-548 (2006).
84. Miller DS, Nobmann SN, Gutmann H, Toeroek M, Drewe J, Fricker G. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol Pharmacol 58: 1357-1367 (2000).
85. Virgintino D, Robertson D, Errede M, Benagiano V, Girolamo F, Maiorano E, et al. Expression of P-glycoprotein inhuman cerebral cortex microvessels. J Histochem Cytochem 50: 1671-1676 (2002).
86. Schlachetzki F and Pardridge WM. P-glycoprotein and caveolin-1 alpha in endothelium and astrocytes of primate brain. Neuroreport 14: 2041-2046 (2003).
87. Bendayan R, Ronaldson PT, Gingras D and Bendayan M. In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Soc DOI: 10.1369/jhc.5A6870.2006 (2006).
88. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B and Wisniewski T. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 159:439-447 (2001).
89. DeMattos R, Bales K, Paul S and Holtzman D. Potential role of endogenous and exogenous Aβ binding molecules in Aβ clearance and metabolism. Aβ Metabolism in Alzheimer's Disease. (Ed. T. Saido). Landes Bioscience 123-139 (2003).
90. Quinn KA, Grimsley PG, Dai YP, Tapner M, Chesterman CN, Owensby DA. Soluble low density lipoprotein receptor-related (LRP) circulates in human plasma. J Biol Chem 272: 23946-23951 (1997).
91. Gorski DH and Walsh K. Control of vascular cell differentiation by homeobox transcription factors. Trends Cardivasc Med 13: 213-220 (2003).
92. Miano JM. Serum response factor: toggling between disparate programs of genes. J Mol cell Cardiol 35: 577-593 (2003).
93. Chen J, Kitchen CM, Streb JW, Miano JM. Myocardin: a component of a molecular switch for smooth muscle differentiation. J Mol cell Cardiol 34: 1345-1356 (2002).
94. Wang Z, Wang DZ, Pipes GC, Olson EN. Myocardin is a master regulator of smooth muscle gene expression. Proc Natl Acad Sci USA 100: 7129-7134 (2003).
95. Miano JM. Channeling to myocardin. Cir Res 95: 340-342 (2004).